Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)

Study Overview
=================
Brief Summary
-----------------
Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.

Detailed Description
-----------------
About 50 patients with a proven breast cancer and bone metastases will be included. First step : staging nuclear bone scan Positron Emission Tomography (PET/CT) MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration Aim : Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results. To calculate cut-off values for DWI for bone and visceral metastases. Second step : therapy follow-up/therapy assessment. Two groups of patients (oncologist takes the decision about therapy) Patients treated by chemotherapy Patients treated by hormonal therapy on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed. End-point: Whole body MR with DWI is useful and reliable to assess the treatment response.

Official Title
-----------------
Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a proven breast cancer (by biopsy or imaging) Bone metastases proven by MR, PET-CT or Bone. Patients with visceral metastases can be included if bone metastases are also present. Patient with an informed consent. Exclusion Criteria: Patients with a single bone metastasis treated by Radiotherapy will be excluded. Patients with contra-indication for MRI: pacemaker, cochlear implant, non MR compatible devices (Baclofenpump). Claustrophobia Patient in a bad general condition.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer patients<br>Breast cancer patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of whole body diffusion weighted MRI in breastcancer patients | whole body MRI will be correlated to the nucleair bone scan and PET-CT | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, metastasis, bone, diffusion MRI